ClinicalTrials.gg
CompletedNCT06906198Updated Apr 2, 2025

Pharmacokinetics of VVN461 Ophthalmic Solution

A Phase 1 interventional study of VVN461 Ophthalmic Solution 1.0% and VVN461 Ophthalmic Solution 0.5% in Healthy Volunteers, sponsored by VivaVision Biotech, Inc. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by VivaVision Biotech, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Mar 2023, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a single-center, double-masked, randomized, vehicle-controlled study conducted in China in adult healthy subjects

Read the detailed description

This is a Phase I, randomized, double-masked, vehicle-controlled study to evaluate the safety, tolerability and pharmacokinetics of 0.25%, 0.5% and 1.0% VVN461 Ophthalmic Solution in healthy male and female volunteers in China.

The study consisted of a screening period (D-7 to D-1), a baseline visit (D-1), a single-dose period (D1), QID multi-dose period (D2 to D5), six times daily multi-dose period (D6 to D9), discharge (D10), and a follow-up/EOS (D16,+1D). During the single-dose period, subjects will receive one drop of VVN461 eye drops (0.25%, 0.5%, or 1.0%) or vehicle in the study eye. For the multi-dose period, subjects will receive one drop of VVN461 eye drop (0.25%, 0.5% or 1.0%) or vehicle in the study eye four or six times a day. PK blood samples will be collected before and after dosing at D1, D5 and D9.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

VivaVision Biotech, Inc is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 50 years at the time of signing the form.
  • Males weighing ≥ 50.0kg and females ≥ 45.0kg; and with a (BMI = weight/height squared) of 19-26 kg/m2 (including thresholds).
  • Best-corrected visual acuity (BCVA) ≥ 0.8 (standard logarithmic scale) in both eyes; intraocular pressure of 11-21 mmHg (including threshold) in both eyes; and slit-lamp examination of the anterior segment of the eye and funduscopic examination (funduscopic photographs) with no significant abnormality or an abnormality judged by the investigator to be not .
  • No clinically significant medical history of the liver, kidneys, gastrointestinal tract, nervous system, respiratory system (e.g., asthma, exercise-induced asthma, ), hematological and lymphatic system, musculoskeletal system, rheumatological immunity, psychiatric abnormalities and metabolic abnormalities
  • Physical examination, vital signs, 12-lead and laboratory tests at screening are within normal values or the abnormalities are not clinically significant.

Exclusion criteria

Exclusion Criteria:

  • Known or to the study drug or its components
  • Anatomical anomalies in either eye
  • History of eye surgery (other than blepharoplasty) or laser treatment of the eye (including keratoconus) in either eye
  • Blepharoplasty on either eye within 3 months prior to screening
  • History of subchoroidal or vitreous injection in either eye
  • Infectious eye disease, immunological eye disease, inflammatory eye disease or ocular trauma in either eye within three months prior to screening;
  • Use of topical ophthalmic medications (including artificial tears, proprietary drops and OTC ophthalmic medications) in either eye within 1 month prior to screening
  • Using contact lens in either eye within 14 days prior to screening or unable to discontinue the use of contact lens during the study
  • A history of eye disease such as glaucoma, corneal opacity, corneal degeneration, corneal dystrophy, uveitis, fundopathy, or other ophthalmic disease in either eye, which is assessed by the investigator to be contraindicated for participation in the trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    VVN461, 1.0%

    VVN461 Ophthalmic Solution, 1.0%

    Drug: VVN461 Ophthalmic Solution 1.0%

  • Experimental
    VVN461, 0.5%

    VVN461 Ophthalmic Solution, 0.5%

    Drug: VVN461 Ophthalmic Solution 0.5%

  • Experimental
    VVN461, 0.25%

    VVN461 Ophthalmic Solution, 0.25%

    Drug: VVN461 Ophthalmic Solution 0.25%

  • Placebo comparator
    Vehicle

    VVN461 Ophthalmic Solution, Placebo

    Drug: VVN461 Ophthalmic Solution Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety outcome

    Incidence of adverse events

    Time frame: Baseline to Day 16

Secondary outcomes

  1. Time to maximum blood level

    Tmax

    Time frame: Maximum seen over Days 1 to 9

  2. Area under the curve of blood levels until last observation

    AUC0-last

    Time frame: Integrated over Days 1 to 9

  3. Area under the curve of blood levels extrapolated to infinity

    AUC0-inf

    Time frame: Integrated over Days 1 to 9

  4. Half life of drug in blood

    t1/2

    Time frame: Integrated over Days 1 to 9

Other outcomes

  1. Maximum concentration of drug in blood

    Cmax

    Time frame: Integrated over Days 1 to 9

07

Study locations

1 site
  • Eye Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325027, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in May 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Apr 2, 2025
StartActual
Mar 1, 2023
Primary completionActual
May 10, 2023
CompletionActual
Dec 22, 2023
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06906198
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Mar 1, 2023
Primary completion
May 10, 2023
Completion
Dec 22, 2023
Last update
Apr 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VVN461

Start the discussion